Johannes A Romijn Selected Research

CNTO 736

1/2009

CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johannes A Romijn Research Topics

Disease

57	Insulin Resistance 08/2021 - 11/2002
40	Type 2 Diabetes Mellitus (MODY) 01/2021 - 05/2003
22	Acromegaly 01/2016 - 03/2003
20	Thyroid Neoplasms (Thyroid Cancer) 05/2011 - 03/2002
17	Obesity 08/2021 - 12/2002
16	Body Weight (Weight, Body) 01/2018 - 08/2003
10	Neoplasms (Cancer) 08/2011 - 03/2002
8	Inflammation (Inflammations) 01/2020 - 08/2006
7	Prolactinoma (Prolactinomas) 01/2014 - 10/2006
7	Cardiovascular Diseases (Cardiovascular Disease) 10/2013 - 02/2005
7	Atherosclerosis 08/2013 - 11/2007
7	Hypertriglyceridemia 12/2011 - 09/2002
7	Hypothyroidism 08/2010 - 07/2007
6	Weight Loss (Weight Reduction) 01/2019 - 07/2007
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2016 - 11/2003
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2016 - 06/2003
6	Pituitary ACTH Hypersecretion 01/2016 - 12/2003
6	Hypopituitarism (Sheehan's Syndrome) 08/2011 - 05/2006
6	Neoplasm Metastasis (Metastasis) 08/2010 - 04/2006
5	Cushing Syndrome 08/2014 - 01/2005
5	Pituitary Neoplasms (Pituitary Adenoma) 04/2011 - 11/2005
4	Hyperglycemia 05/2016 - 06/2005
4	Hyperinsulinism (Hyperinsulinemia) 07/2015 - 10/2004
4	Paraganglioma (Paragangliomas) 07/2012 - 02/2010
4	Primary Hyperparathyroidism 01/2011 - 02/2010
4	Lipodystrophy 01/2006 - 11/2002
3	Hypertension (High Blood Pressure) 12/2014 - 12/2007
3	Adrenal Insufficiency (Adrenal Gland Hypofunction) 10/2014 - 06/2005
3	Diabetic Cardiomyopathies 10/2013 - 11/2008
3	Weight Gain 01/2013 - 10/2002
3	Glucose Intolerance 01/2012 - 10/2002
3	Ischemia 07/2011 - 04/2009
3	Hyperparathyroidism 01/2011 - 08/2010
3	Adenoma (Adenomas) 01/2009 - 11/2005
3	Hyperthyroidism 01/2009 - 02/2007
3	Fatigue 11/2008 - 11/2004
2	Non-alcoholic Fatty Liver Disease 01/2021 - 01/2017

Drug/Important Bio-Agent (IBA)

50	Glucose (Dextrose)FDA LinkGeneric 08/2021 - 11/2002
40	Insulin (Novolin)FDA Link 01/2021 - 06/2003
28	Triglycerides (Triacylglycerol)IBA 01/2021 - 08/2003
11	Fatty Acids (Saturated Fatty Acids)IBA 01/2018 - 05/2003
11	Growth Hormone (Somatotropin)IBA 01/2016 - 02/2004
10	LipidsIBA 01/2017 - 02/2005
10	Nonesterified Fatty Acids (NEFA)IBA 05/2016 - 11/2002
9	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2016 - 06/2003
9	Apolipoproteins E (ApoE)IBA 08/2013 - 11/2003
8	GlucocorticoidsIBA 08/2014 - 06/2004
8	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 06/2009 - 03/2003
8	Insulin-Like Growth Factor I (IGF-1)IBA 01/2009 - 12/2002
7	Glucagon-Like Peptide 1 (GLP 1)IBA 08/2021 - 08/2010
7	CatecholaminesIBA 12/2014 - 07/2008
7	CholesterolIBA 02/2012 - 01/2004
7	Thyroxine (Levothyroxine)FDA LinkGeneric 05/2011 - 07/2002
7	Hormones (Hormone)IBA 01/2010 - 03/2003
6	Dopamine Agonists (Dopamine Agonist)IBA 01/2014 - 11/2005
6	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 05/2011 - 07/2002
6	Thyroid HormonesIBA 08/2010 - 07/2007
6	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 12/2009 - 03/2005
6	ApolipoproteinsIBA 05/2009 - 05/2003
6	Octreotide (Sandostatin)FDA LinkGeneric 09/2008 - 03/2003
5	Cabergoline FDA LinkGeneric 01/2014 - 11/2005
4	Messenger RNA (mRNA)IBA 06/2020 - 03/2005
4	CytokinesIBA 01/2020 - 09/2006
4	Bile Acids and Salts (Bile Acids)IBA 01/2019 - 04/2006
4	Blood Glucose (Blood Sugar)IBA 10/2014 - 06/2005
4	VLDL LipoproteinsIBA 05/2009 - 03/2004
4	Bexarotene (LGD1069)FDA Link 05/2009 - 04/2006
4	Retinoid X Receptors (Retinoid X Receptor)IBA 05/2009 - 07/2007
4	Proteins (Proteins, Gene)FDA Link 04/2009 - 12/2002
4	pegvisomant FDA LinkGeneric 05/2008 - 01/2005
3	Pharmaceutical PreparationsIBA 01/2022 - 01/2007
3	ProlactinIBA 01/2014 - 01/2009
3	Metformin (Glucophage)FDA LinkGeneric 10/2013 - 04/2009
3	Pioglitazone (Actos)FDA Link 10/2013 - 04/2009
3	AdipokinesIBA 01/2013 - 07/2005
3	Lipoproteins (Lipoprotein)IBA 01/2013 - 09/2002
3	Rosiglitazone (Avandia)FDA Link 01/2013 - 08/2003
3	Phosphotransferases (Kinase)IBA 02/2012 - 02/2008
3	Adenosine Triphosphate (ATP)IBA 12/2011 - 07/2003
3	very low density lipoprotein triglycerideIBA 12/2011 - 05/2003
3	Dobutamine FDA LinkGeneric 07/2011 - 04/2009
3	Cholesterol Ester Transfer ProteinsIBA 07/2010 - 05/2008
3	Estrogens (Estrogen)FDA Link 06/2010 - 06/2005
3	Dopamine (Intropin)FDA LinkGeneric 03/2010 - 04/2009
3	IodineIBA 12/2009 - 07/2002
3	Phosphates (Orthophosphate)IBA 10/2009 - 07/2003
3	lanreotide (Somatuline)FDA Link 06/2009 - 11/2005
3	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2009 - 06/2004
3	Thyroglobulin FDA Link 04/2008 - 07/2002
3	Apolipoprotein C-I (Apolipoprotein C1)IBA 11/2007 - 01/2004
3	IodidesIBA 04/2004 - 03/2002
2	CarbohydratesIBA 01/2021 - 12/2004
2	FructoseIBA 11/2017 - 12/2016
2	Dietary Carbohydrates (Carbohydrate, Dietary)IBA 12/2016 - 12/2004

Therapy/Procedure

32	Therapeutics 01/2020 - 03/2002
15	Radiotherapy 01/2016 - 11/2004
9	Caloric Restriction 12/2017 - 09/2008
7	Aftercare (After-Treatment) 04/2011 - 11/2004
6	Bariatric Surgery 08/2021 - 05/2009
3	Parathyroidectomy 01/2011 - 02/2010